Surrozen, Inc./DE Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
Surrozen, Inc./DE (SRZN) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2023-11-08
- Surrozen, Inc./DE other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-09-30 was $0.00.
- Surrozen, Inc./DE other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-06-30 was $0.00.
- Surrozen, Inc./DE other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-03-31 was $0.00.
- Surrozen, Inc./DE other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00.
- Surrozen, Inc./DE other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2022 was $0.00.
- Surrozen, Inc./DE other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-31 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $0.00 10-K · filed 2022-03-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |